BIIB
Biogen-IDEC Corporation

Conference date: October 22, 2014 @ 5:30 AM Pacific Time

Can Biogen Idec Take Wing With Tecfidera? [July 29, 2014]
Biogen Idec: Too High Too Fast? [April 29, 2013]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Biogen Idec: Q3 Clues to Value [November 2, 2011]

Analyst Conference Summaries available:

2014
Biogen-Idec analyst conference summary Q1 2014
Biogen-Idec analyst conference summary Q2 2014
Biogen-Idec analyst conference summary Q3 2014
 
04/23/2014
07/23/2014
10/22/2014
 
Q1
Q2
Q3
 
2013
Biogen-Idec analyst conference summary Q1 2013
Biogen-Idec analyst conference summary Q2 2013
Biogen-Idec analyst conference summary Q3 2013
Biogen-Idec analyst conference summary Q4 2013
04/25/2013
07/25/2013
10/28/2013
01/29/2014
Q1
Q2 
Q3
Q4
2012
Biogen-Idec analyst conference summary Q1 2012
Biogen-Idec analyst conference summary Q2 2012
Biogen-Idec analyst conference summary Q3 2012
Biogen-Idec analyst conference summary Q4 2012
05/01/2012
07/24/2012
10/25/2012
01/28/2013
Q1
Q2 
Q3
Q4
2011
Biogen-Idec analyst conference summary Q1 2011
Biogen-Idec analyst conference summary Q2 2011 
Biogen-Idec analyst conference summary Q3 2011
Biogen-Idec analyst conference summary Q4 2011
04/21/2011
07/26/2011 
 10/28/2011
01/31/2012
Q1
Q2
Q3
 Q4
2010
Biogen-Idec analyst conference summary Q1 2010
 Biogen-Idec analyst conference summary Q2 2010
 Biogen-Idec analyst conference summary Q3 2010
Biogen-Idec analyst conference summary Q4 2010
04/20/2010
 07/20/2010
 10/26/2010
 02/01/2011
Q1
Q2 
Q3
 Q4
2009
 Biogen-Idec analyst conference summary q1 2009
Biogen-Idec analyst conference summary Q2 2009
 Biogen-Idec analyst conference summary Q3 2009
Biogen-Idec analyst conference summary Q4 2009
04/16/2009
07/16/2009 
 10/20/2009
02/09/2010 
Q1
 Q2
 Q3
Q4 
2008
BIIB analyst conference summary Q1 2008
BIIB analyst conference summary Q2 2008
BIIB analyst conference summary Q3 2008 Biogen Idec
Biogen analyst conference summary Q4 2008
04/23/2008
07/22/2008
10/21/2008
02/06/2009
Q1
Q2
Q3
Q4
2007
BIIB Q4 2007 analyst conference summary
BIIB Q3 2007 conference summary
biib Q2 2007
BIIB summary
02/06/2008
10/23/2007
07/24/2007
05/02/2007
Q4
Q3
Q2
Q1
2006
02/15/2007
10/31/2006
07/26/2006
04/26/2006
Q4
Q3
Q2
Q1

Biogen Idec: Is there More Value? [July 11, 2011]
Biogen Idec PML Test Approved in Europe, Changing Tysabri Outlook [March 15, 2011]
Biogen Idec Hemophilia Therapies [September 30, 2010]
Gilenya, Biogen Idec, and MS [September 22, 2010]
FDA February 5, 2010 Tysabri and PML letter
Biogen Research and Development Presentation notes [March 25, 2009]
Biogen Idec Growth Acceleration [October 27, 2008 blog]
Biogen Idec: Will it Recover? [September 1, 2008 blog]
Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]

First acquired in February 2008

Biogen Idec is a biotechnology pharmaceutical company which markets Rituxan, Zevalin, Avonex, Fumaderm, and Tysabri.

Biogen Idec Web site:

main page
investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.